MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.leukres.2026.108230

Медицинская библиотека · Leukemia research · 2026

An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myeloma.

Corradini Paolo, Musto Pellegrino, Galeone Carlotta, Mariani Paolo, Resci Federica, Cavo Michele

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Refractoriness to lenalidomide in patients treated for multiple myeloma (MM) is increasing. Exploring opinions of experts on the burden of lenalidomide-refractory MM and on current and future therapeutic options is critical for optimizing care in this setting.

METHODS

From January to July 2024, we conducted a modified Delphi study involving 12 haematologists in Italy. The project followed the best practices for Delphi studies, including anonymity, iteration, controlled feedback, definition and analysis of consensus.

RESULTS

Two rounds were required to complete the Delphi process. Participation of clinicians was complete. Experts agreed that more than 80% of Italian patients starting second-line therapy are expected to be refractory to lenalidomide in 2026. Full consensus emerged (100% of panellists) that the main clinical unmet needs in this patient setting are the approval and access to novel (immuno)therapies with new mechanisms of action. More than two-thirds of panellists also agreed, in principle, to the use of T-cell redirecting therapies, including CAR-T and bispecific antibodies, from the second-line of treatment onwards. No clear patient characteristics emerged to drive therapeutic options in specific subgroups of subjects with lenalidomide-refractory MM.

CONCLUSIONS

This Delphi consensus study reported a major clinical unmet need of newly available and accessible therapeutic options for lenalidomide-refractory MM, already starting from the second-line of treatment.

Для цитирования: Corradini Paolo, Musto Pellegrino, Galeone Carlotta, Mariani Paolo, Resci Federica, Cavo Michele. An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myeloma.. Leukemia research. 2026. DOI: 10.1016/j.leukres.2026.108230.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.